ValiRx plc

Homepage Draft

Default features description for sign up page.

Contact Us

Careers

Collaborative Pipeline

Board & Management Team

Privacy Policy

How we work

Strategy & Vision

Updates

Analyst Research

AIM Rule 26

Share Price Information

Reports, AGMs & Presentations

Regulatory News

Webinars

Partnering & Useful Links

Therapeutic Areas

Inaphaea Biolabs

Evaluation Pipeline

Our Pipeline

Home

DM Sans

ValiRx (LSE: VAL) is a UK life sciences company pioneering next-generation therapies in cancer and women's health — built for patients, designed for investors.

ValiRx (LSE: VAL) is a UK-based life sciences company focused on advancing cutting-edge therapies in healthcare.

We're a mission-driven team committed to delivering innovative solutions, keeping our shareholders informed and engaged throughout our journey.

Our focus spans clinical developments and therapeutic innovation, where we're working to identify key milestones and communicate the value of our progress to ensure shareholders remain aligned with our mission.

Watch Mark Eccleston talk about the importance of a strong investor community:

Better, direct communication with the ValiRx team

Our priority areas of therapeutic focus are cancer and women's health. We select only the most promising pre-clinical projects for progression through the drug development process, to become ready for clinical trials. We currently have a number of projects within our pipeline.

We are a team of scientists, technologists and business leaders, committed to providing the framework required for effective and efficient drug development. Our cross-disciplinary approach connects scientific rigour with commercial strategy — accelerating value creation across every stage of the development pipeline.

We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

Explore ValiRx

Latest Announcements

Latest Updates